Pulmonary Arterial Hypertension
10 drugs22,355 FAERS reportsMedDRA PT
GET
/api/v1/reaction/pulmonary-arterial-hypertensionReference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. The drugs below are ranked by how often this reaction appears on FAERS reports for each drug — high share does not mean the drug caused the reaction, and absence from this list does not mean the reaction never occurred. This is not a symptom checker.
DefinitionNLM MeSH D000081029
A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.
Source: U.S. National Library of Medicine — MeSH (Pulmonary Arterial Hypertension)
Drugs reporting Pulmonary Arterial Hypertension (10)
Share = reports listing this reaction ÷ total matched reports for the drug. — means the upstream totals query failed at ingest and the denominator is unknown.
- 1Vitamin K2212%
- 2Epoprostenol1,1068.6%
- 3Selexipag1,6826.7%
- 4Iloprost586.5%
- 5Macitentan3,2744.8%
- 6Treprostinil4,4393.6%
- 7Tadalafil2,8622.9%
- 8Ambrisentan3,3392.7%
- 9Sildenafil3,3032.6%
- 10Bosentan2,290—
Related reactions
Other reactions most often co-reported on the same drug set. Ranked by Jaccard similarity over drug-id sets — pure data-derived co-occurrence, not a clinical relationship.
- Fluid Retention8 shared · 0.33
- Dyspnoea Exertional5 shared · 0.25
- Pain In Jaw3 shared · 0.23
- Pulmonary Hypertension3 shared · 0.19
- Nasal Congestion2 shared · 0.11
- Flushing5 shared · 0.07
- Oedema Peripheral5 shared · 0.06
- Chest Pain8 shared · 0.05
- Syncope2 shared · 0.05
- Oxygen Saturation Decreased2 shared · 0.03
Literature
Recent PubMed references pinned to Pulmonary Arterial Hypertension as a MeSH major topic. About the reaction term itself — not about any specific drug.
- Integrative transcriptomic analysis identifies immune-associated candidate genes and altered immune cell infiltration in pulmonary arterial hypertension.PloS one · 2026 · Yang X, Zhou B, Yang Y, et al.PMID 42172296DOI 10.1371/journal.pone.0350015
- Hemodynamic and metabolomic responses to infusion of GLP-1 agonist exenatide in pulmonary arterial hypertension.JCI insight · 2026 · Samaranayake CB, Niglas M, Baxan N, et al.PMID 42171611DOI 10.1172/jci.insight.202660
- Sotatercept reduces bone morphogenetic protein signaling in patients with pulmonary arterial hypertension.Science translational medicine · 2026 · Jones RJ, De Bie EMDD, Deliu N, et al.PMID 42160453DOI 10.1126/scitranslmed.ads5175
- Targeted Delivery of GLUT1 Inhibitor via Macrophage Nanovesicles for Pulmonary Arterial Hypertension Therapy.Journal of extracellular vesicles · 2026 · Guo Y, Lu S, Wang W, et al.PMID 42139313DOI 10.1002/jev2.70294
- Exploring the Lung-Liver Axis in Pulmonary Arterial Hypertension.Comprehensive Physiology · 2026 · Singh N, Lawson J, Ragavendran A, et al.PMID 42138622DOI 10.1002/cph4.70171
- Amonafide Targeting NTSR1-PI3K/AKT/mTOR Signaling Attenuates Vascular Remodeling in Pulmonary Arterial Hypertension.Journal of the American Heart Association · 2026 · Zhu YJ, Kou JJ, Bo YC, et al.PMID 42132175DOI 10.1161/JAHA.125.045580
Note. FAERS reports are voluntarily submitted and are NOT incidence rates, signals, or causal evidence. Counts reflect reporting volume, not how often a reaction occurs. Reference statistics only.